Table 2.
Achieved number or ratio regarding improvement of cardiometabolic risks in patients with early-stage type 2 diabetes
| Endpoint | Dapagliflozin group (n = 160) | Sitagliptin group (n = 159) | P-value |
|---|---|---|---|
| n (%) | n (%) | ||
| Composite endpoint | 39 (24.4) | 22 (13.8) | 0.017 |
| HbA1c level maintenance ≤ 7.0% (53 mmol/mol) | 81 (49.4) | 80 (50.0) | 0.91 |
| Avoidance of hypoglycemia | 141 (88.7) | 144 (92.3) | 0.27 |
| More than 3.0% body weight loss | 87 (54.4) | 31 (19.6) | < 0.001 |
Data are presented as frequency (percentage). P-values for between-group comparisons were obtained using the chi-square test